This technology is a method to generate squamous epithelial 3D organoids that can mimic the natural physiology of tissues and be used as a personalized pathology model.

This technology is a computational pipeline designed to identify major kinases in different cancer subtypes for the development of precision cancer therapeutics.

This technology is an automated imaging analysis platform for identifying and quantifying biomarkers that can be used to predict lung adenocarcinoma subtypes.

This technology is patient-specific engineered model of bone marrow for diagnostics and research of cancer progression using a sample of patient’s serum.

This technology is an optical catheter method for the analysis of uterine tissue using spectrometry without removing a sample from the patient.

This technology is a SLAMF6 bispecific antibody to enhance T-cell activation through compartmentalization that can be used for tumor treatments.

This technology assesses the role of irradiation therapy for cancer treatment and its impact on adenosine signaling.

This technology is a method employing trained algorithms to tune portal vein phase acquisition for accurate measurement of vascular density and tumor volume.

This technology is two methods, called ssg-MeDIP-Seq and sscf-MeDIP-Seq, for improved tumor detection using detection of DNA methylation density in genomic DNA, and of hemi-methylated regions in plasma cell-free DNA.

This technology is a cancer immunotherapy platform that activates CD28-CD8+ T-cells via the CD58:CD2 axis.

Hypoxia is a characteristic feature of glioblastoma, as well as many other malignant tumors, and is associated with poor patient prognosis.

This technology is an RNA templated genome editing technique that can be utilized in any organism, without the typical requirement for homologous recombination.

This technology is a method for determining the presence or absence of head and neck cancer through the detection of cancer-associated proteins on extracellular vesicles isolated from patients.

This technology is a targeted anti-tumor agent designed to treat adenoid cystic carcinoma (ACC) by utilizing retinoid receptor modulation to promote cancer cell differentiation and selective cell death.

This technology is a method of isolating polynucleotides from cell-free non-invasive bodily samples and sequencing them to detect methylated DNA to identify early tumors.